NCT04145375View on ClinicalTrials.gov

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

mCRPC

Interventions

DRUG

ZEN003694

Up to 120mg

DRUG

Enzalutamide

160mg

Trial Locations (2)

94104

University of California San Francisco Medical Center, San Francisco

97239

Oregon Health & Science University, Portland

Sponsors

Lead Sponsor

Zenith Epigenetics

All Listed Sponsors

lead

Zenith Epigenetics

INDUSTRY